[New targets and new drugs in thoracic oncology]

Area of Science:

• Oncology
• Molecular Biology
• Thoracic Malignancies

Background:

• Significant progress in understanding oncogenesis over the past 20 years.
• Key oncogenic drivers in thoracic tumors include EGFR, KRAS mutations, and EML4-ALK translocations, primarily in adenocarcinomas.
• Emerging molecular targets and abnormalities identified across various lung cancer subtypes.

Purpose of the Study:

• To review novel targeted agents for lung cancer.
• To highlight recent advancements in identifying new molecular targets.
• To discuss therapeutic strategies targeting identified signaling pathways.

Main Methods:

• Literature review of oncogenic mechanisms and targeted therapies in lung cancer.
• Identification of key molecular targets and their associated abnormalities.
• Analysis of therapeutic strategies, including monoclonal antibodies and tyrosine kinase inhibitors.

Main Results:

• Established oncogenic factors: EGFR, KRAS, EML4-ALK.
• Newly identified targets: BRAF mutations, HER2, PI3K, ROS1, KIF5B-RET.
• Therapeutic strategies involve pathway inhibition; some are approved, others in clinical trials.

Conclusions:

• Novel molecular targets are expanding treatment options for lung cancer.
• Targeted therapies, including inhibitors and antibodies, show promise.
• Ongoing clinical trials are evaluating new agents for thoracic oncology.